Navigation Links
Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
Date:6/18/2008

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organization serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States and worldwide. The agreement provides comprehensive licensing rights and patent protection relating to Canopus' Phase II oncology drug candidate, CB1400.

"Securing the rights to the WARF patents strengthens Canopus BioPharma's intellectual property position for future licensing opportunities of CB1400, one of our most exciting products," said Patrick Prendergast, Chairman and Chief Executive Officer of Canopus BioPharma. "In the near future, we expect to announce important results from our studies using CB1400, which will further validate the potential significance of our drug for oncology and related indications."

Canopus BioPharma expects to develop CB1400 as a method for preventing and reducing mucositis (lesions in the gastrointestinal and oral mucosa caused by chemo- and/or radiotherapy). The domestic market alone for a preventative anti-mucositis agent is estimated to be over $1 billion per annum. The compound underlying CB1400 had been previously developed and patented by a major pharmaceutical company as an anti-parasitic agent. Canopus discovered that this approved drug was highly effective for an alternative indication, specifically for use in preventing mucositis. Canopus BioPharma's market opportunity with CB1400 includes various applications associated with cancer therapy and cancer treatment side effects.

CB1400, a former anti-schistosomal drug
'/>"/>

SOURCE Canopus BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mylan Inc. (Nasdaq: MYL ) today announced that it has ... amount of 7.625% Senior Notes due 2017 and $700 million ... is using $1.0 billion of the net proceeds from ... loans, thereby reducing senior secured leverage and extending the maturity profile ...
... SHENZHEN, China , May 19 /PRNewswire-Asia/ ... Medical" or the "Company"), a leading manufacturer of,medical dressings, ... consumer products industries, announced today that in,connection with the ... common stock, par value $0.001 per share, ...
Cached Medicine Technology:Mylan Announces Completion of Senior Notes Offering 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 3Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 4
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 According to ... Machine Vision Market by Technology (ICS, MES, ERP, ... Components (Camera, FGOL), Application (Process, Discrete) - Global ... by MarketsandMarkets, the Mexican market is expected to ... by 2020. , Browse 70 market data Tables ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... 2014 Shabaikai is an ambitious historical ... the Pomo Indians located on the shores of Russian ... Shabaikai, meaning ‘crooked snake’. Clarkson takes the reader into ... violence of prohibition and organized crime, providing a glimpse ... the most powerful men in the world convene the ...
Breaking Medicine News(10 mins):Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... Clemson University researcher Julia Frugoli has received $132,769 as ... from the National Science Foundation to continue her study ... other to control their growth and development. The ... College of Agriculture, Forestry & Life Sciences, genetics and ...
... , MONDAY, May 14 (HealthDay News) -- In black ... arteries in the eye,s retina (retinal arteriolar narrowing) is ... study finds. , "Retinal arteriolar narrowing has long been ... hypertension [high blood pressure] and cardiovascular disease," Dr. Monique ...
... Philadelphia, PA, May 14, 2012 Health professionals commonly say, ... but is there any scientific basis for the advice? ... your past experience with needle pricks, along with information you ... is published in the May issue of Pain . ...
... A new type of artificial eye system could one day ... to degenerative eye diseases such as macular degeneration, according to ... tiny solar panel-like cells that are surgically placed beneath the ... with a miniature camera, and a pocket PC that processes ...
... examining the effects of resveratrol on individuals with mild ... as more than two dozen academic institutions recruit volunteers ... Ph.D., director of Georgetown University Medical Center,s Memory Disorders ... Resveratrol is a compound found in red grapes, ...
... (HealthDay News) -- Doing more repetitions with less weight ... training with heavy weights, a new Canadian study indicates. ... yourself to the point of fatigue, according to the ... examined how different combinations of weight loads and repetitions ...
Cached Medicine News:Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2Health News:To avoid pain during an injection, look away 2Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 3Health News:With Weights, You Can Lighten Your Load 2
... PreVue B. Burgdorferi Antibody Detection Assay is ... the qualitative presumptive (first step) detection of ... in human serum or whole blood. Rapid ... accuracy make the Wampole PreVue B. burgdorferi ...
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
Medicine Products: